Interferon beta-1b: all 24 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedNCT01753570Phase 3Results posted
- Natalizumab De-escalation With Interferon Beta-1bCompletedNCT01144052Phase 4Results posted
- BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New DoseCompletedNCT00459667Phase 3Results posted
- Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple SclerosisCompletedNCT00370071Phase 3Results posted
- Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or RebifCompletedNCT00317941Phase 4Results posted
- Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple SclerosisCompletedNCT00235989Phase 2Results posted
- BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up StudyCompletedNCT00185211Phase 3Results posted
- Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRICompletedNCT00176592Phase 4Results posted
- IFN-beta 1b and Remdesivir for COVID19Status unknownNCT04647695Phase 2
- IFN Beta-1b and Ribavirin for Covid-19Status unknownNCT04494399Phase 2
- Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19Status unknownNCT04465695Phase 2
- Double Therapy With IFN-beta 1b and HydroxychloroquineCompletedNCT04350281Phase 2
- An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical TrialCompletedNCT04343768Phase 2
- Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV TreatmentCompletedNCT04276688Phase 2
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyCompletedNCT03177083Phase 4
- Comparison Study of PF530 and Betaferon in Healthy SubjectsCompletedNCT02474134Phase 1
- Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT01701856Phase 4
- Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1bCompletedNCT01111656Phase 2
- BEYOND Pilot StudyCompletedNCT00893217Phase 2
- Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnNCT00313976Phase 3
- Combination Therapy of Betaseron-Prograf in Multiple SclerosisStatus unknownNCT00298662Phase 2
- An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MSCompletedNCT00206648Phase 4
- Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral CardiomyopathyCompletedNCT00185250Phase 2
- BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsCompletedNCT00099502Phase 3